Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

The decision also marks the FDA’s first approval of a PROTAC therapy, a type of targeted protein-degrading drug. ・The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease ...

Vepdegestrant introduces a novel mechanism in oncology: targeted protein degradation to remove cancer-driving proteins. This approach may overcome endocrine resistance, a key challenge in advanced ...

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

VERITAC-2 trial shows vepdegestrant improves progression-free survival in ESR1-mutant breast cancer, marking a clinical milestone for PROTAC therapy. The trial did not reach statistical significance ...

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors ...

Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...

ARV-393 is an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell ...